Stock detail

Uniqure (QURE) stock price, chart, and key data

View Uniqure stock price, chart movement, and headline metrics on Woodstock's stock detail page.

QURE

Stock detail

Uniqure

QURE · XNAS

+$7.28 (+18.06%) past day

$47.60

Overnight $47.67 (+0.15%)

XNAS24/5 tradingLast updated: Jul 25, 01:01 PM

Key metrics

Financials

Quarterly revenue, profitability, and balance-sheet snapshot

0.00-0.30-0.60-0.89-1.19
FY2025 Q2Reported Revenue: €5MExpected Revenue: €5MNet income: -€38MExpected EPS: -0.60
FY2025 Q3Reported Revenue: €3MExpected Revenue: €4MNet income: -€81MExpected EPS: -1.19
FY2025 Q4Reported Revenue: €5MExpected Revenue: €5MNet income: -€37MExpected EPS: -0.47
FY2026 Q1Reported Revenue: €3MExpected Revenue: €4MNet income: -€54MExpected EPS: -0.73
FY2026 Q2Expected Revenue: €5M
FY2026 Q3Expected Revenue: €5M
5.1M-12M-29.1M-46.3M-63.4M-80.5M
FY25 Q2Q3Q4FY26 Q1Q2Q3

Operating income & Operating cash flow

Quarterly revenue, profitability, and balance-sheet snapshot

0-15.5M-31M-46.5M-62.1M-77.6M
FY2024 Q4Operating income: -$42MOperating cash flow: -$53M
FY2025 Q1Operating income: -$38MOperating cash flow: -$44M
FY2025 Q2Operating income: -$42MOperating cash flow: -$40M
FY2025 Q3Operating income: -$49MOperating cash flow: -$16M
FY2025 Q4Operating income: -$50MOperating cash flow: -$78M
FY2026 Q1Operating income: -$47MOperating cash flow: -$38M
FY24 Q4FY25 Q1Q2Q3Q4FY26 Q1

Total assets & Total liabilities

Quarterly revenue, profitability, and balance-sheet snapshot

888.4M710.7M533M355.4M177.7M0
FY2024 Q4Total assets: $557MTotal liabilities: $563M
FY2025 Q1Total assets: $605MTotal liabilities: $572M
FY2025 Q2Total assets: $585MTotal liabilities: $589M
FY2025 Q3Total assets: $888MTotal liabilities: $660M
FY2025 Q4Total assets: $825MTotal liabilities: $626M
FY2026 Q1Total assets: $779MTotal liabilities: $629M
FY24 Q4FY25 Q1Q2Q3Q4FY26 Q1

Total equity & Shares outstanding

Quarterly revenue, profitability, and balance-sheet snapshot

228.7M181.6M134.5M87.4M40.3M-6.8M
FY2024 Q4Total equity: -$7MShares outstanding: 54.1M
FY2025 Q1Total equity: $34MShares outstanding: 54.7M
FY2025 Q2Total equity: -$4MShares outstanding: 54.9M
FY2025 Q3Total equity: $229MShares outstanding: 62.3M
FY2025 Q4Total equity: $199MShares outstanding: 62.5M
FY2026 Q1Total equity: $149MShares outstanding: 63.1M
FY24 Q4FY25 Q1Q2Q3Q4FY26 Q1

Day range

$37.47 - $41.65

52-week range

$8.73 - $71.50

Close price

$39.43

Market cap

$2.7B

P/E ratio

-56

Beta

0.9

Financials

FY2026 Q1

Operating income

-$47M

Operating cash flow

-$38M

EPS

Shares outstanding

63.1M

Total assets

$779M

Total equity

$149M

Total liabilities

$629M

About the company

UNIQURE BV

uniQure is a Dutch biopharmaceutical company which makes gene therapies. It has developed several adeno-associated virus gene therapies.

Analyst rating summary

A current read on analyst sentiment from the insight feed.

Mean target

$66.33

Current price $38.45
Low$37.00High$95.00

10

Buy

/ 11

Recent calls

06/29/2026

H.C. Wainwright

Patrick Trucchio

Buy · Price target $80.00

06/24/2026

Mizuho Securities

Uy Ear

Buy · Price target $68.00

06/22/2026

Barclays

Eliana Merle

Buy · Price target $65.00

Ticker holders

Review politician disclosures and insider transactions in tabs.

No holder data is available for this category yet.

Market action

A concise summary of the latest filing, transaction, or market-moving item.

uniQure N.V. insider Matthew C. Kapusta reported a same-day option exercise and sale of ordinary shares on July 2, 2026. The Form 4, filed July 7, shows that Kapusta exercised a stock option using transaction code **M**, acquiring **21,082 ordinary shares** at an exercise price of **$19.39 per share**. The option was already fully vested, with the filing noting that the stock option vested in full on **January 26, 2022**. Following the exercise, Kapusta’s direct holdings rose to **540,309 ordinary shares**. He then sold the same total number of shares—**21,082 ordinary shares**—in three open-market sale transactions reported under transaction code **S**. The sales were made under a prearranged trading plan adopted on **October 5, 2025**, intended to comply with **Rule 10b5-1** under the Securities Exchange Act of 1934. The first sale covered **9,200 shares** at a weighted average price of **$44.43** per share, with individual trade prices ranging from **$44.10 to $44.

24/5 Trading

Act on the stock when the timing works for you.

With Woodstock, you can move from chart review to order placement in one flow. Trade eligible US stocks 24/5, even outside regular market hours.

*24-hour trading is available except during system maintenance. Some stocks are not eligible for extended-hours trading.

Download the app
24/5 trading chart preview

Sign Up

Scan the QR code to get started

Contact via LINE

Scan the QR code to get started

LINE QR Code